Location History:
- Solna, SE (2012 - 2018)
- Stockholm, SE (2021 - 2023)
Company Filing History:
Years Active: 2012-2023
Title: Arezou Zargari: Innovator in Oligonucleotide Therapy
Introduction
Arezou Zargari is a prominent inventor based in Solna, Sweden, known for his significant contributions to the field of oligonucleotide therapy. With a total of 13 patents to his name, Zargari has made remarkable strides in developing treatments for inflammatory bowel disease.
Latest Patents
Zargari's latest patents include innovative therapies that utilize specific oligonucleotide sequences. One notable invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2) for use in treating inflammatory bowel disease in human subjects. This treatment involves administering individual doses ranging from 100 mg to 350 mg on at least four separate occasions, with each occasion spaced a week apart. Another patent focuses on Cobitolimod, which also employs the same oligonucleotide sequence for treating inflammatory bowel disease, with doses between 150 mg and 350 mg administered on at least two occasions, three weeks apart.
Career Highlights
Zargari is currently associated with Index Pharmaceuticals AB, where he continues to advance his research and development efforts in the pharmaceutical industry. His work has garnered attention for its potential to improve the quality of life for individuals suffering from inflammatory bowel disease.
Collaborations
Zargari collaborates with notable colleagues, including Oliver Von Stein and Charlotte Admyre, who contribute to the innovative environment at Index Pharmaceuticals AB.
Conclusion
Arezou Zargari stands out as a key figure in the field of oligonucleotide therapy, with a focus on developing effective treatments for inflammatory bowel disease. His contributions through patents and collaborations highlight his commitment to advancing medical science.